
==== Front
Curr Oncol Rep
Curr Oncol Rep
Current Oncology Reports
1523-3790
1534-6269
Springer US New York

38954315
1570
10.1007/s11912-024-01570-1
Review
Systemic Therapy for Non-Melanoma Skin Cancers: Latest Advances
Lessans Spencer 1
O’Connell Katie A. 2
Choe Jennifer jennifer.choe@vumc.org

3
1 https://ror.org/05dq2gs74 grid.412807.8 0000 0004 1936 9916 Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, TN USA
2 https://ror.org/05dq2gs74 grid.412807.8 0000 0004 1936 9916 Department of Dermatology, Vanderbilt University Medical Center, Nashville, TN USA
3 https://ror.org/05dq2gs74 grid.412807.8 0000 0004 1936 9916 Department of Hematology/Oncology, Vanderbilt University Medical Center, Preston Research Building 790, 2220 Pierce Ave, Nashville, TN 37232 USA
2 7 2024
2 7 2024
2024
26 9 11201133
11 6 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Purpose of Review

This review provides an update on approved and emerging systemic therapies in the treatment of locally advanced or metastatic non-melanoma skin cancers (squamous cell carcinoma, basal cell carcinoma, Merkel cell carcinoma).

Recent Findings

Many studies demonstrate the effectiveness of immunotherapy for all types of non-melanoma skin cancer. For basal cell carcinoma (BCC), hedgehog inhibitors (HHI) remain first-line but with poor tolerability. Numerous clinical trials studying both neoadjuvant and adjuvant use of anti-PD-1 and anti-PD-L1 therapies in advanced NMSC are under investigation.

Summary

There is a growing number of systemic therapies available to treat non-melanoma skin cancers. The advent of immunotherapy has revolutionized the field and greatly improved survival compared to historical survival rates with cytotoxic chemotherapy.

Keywords

Squamous cell carcinoma
Basal cell carcinoma
Merkel cell carcinoma
Immunotherapy
Neoadjuvant
issue-copyright-statement© Springer Science+Business Media, LLC, part of Springer Nature 2024
==== Body
pmcIntroduction

Non-melanoma skin cancer (NMSC) is a term used to describe a broad range of skin malignancies. It most commonly includes keratinocyte carcinomas: cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC), but also includes Merkel cell carcinomas (MCC). There are approximately 5.4 million cases of NMSC each year, 80% of which occur in people aged 60 years or older [1, 2]. NMSC is the most common cancer type by incidence and, while it has a low mortality rate, the total number of mortalities is close to that of melanoma due to its high prevalence [3]. The incidence of both BCC and SCC have steadily increased [4]. This is thought to be due, at least in part, to the cumulative exposure to ultraviolet (UV) radiation, which is associated with 90% of NMSC cases [5].

Surgical resection utilizing peripheral and deep margin assessment (PDEMA) which includes Mohs surgery and surgical excision using standard vertical sectioning remain the mainstay of treatment for the majority of cases amenable to resection [6]. For cases not amenable to surgical resection, cytotoxic chemotherapy had historically been utilized. Studies looking at outcomes for patients with advanced or metastatic BCC or CSSC were limited to case series, small sample sizes, and lack of randomization, but had limited convincing efficacy prior to the advent or targeted molecular therapies and immunotherapy [7]. In 2011, the first checkpoint inhibitor, ipilimumab, was approved for use in metastatic melanoma followed by approval of pembrolizumab [8]. Since then, immunotherapy has revolutionized cancer therapy, expanding not only into other non-melanoma skin cancers but across solid tumors. The growth of immunotherapy and targeted molecular therapy in treatment of locally advanced and metastatic NMSC has significantly changed treatment options currently available to patients and therefore survival in this population. This review summarizes systemic therapies currently available for treatment of locally advanced and metastatic non-melanoma skin cancers and highlights emerging therapies under investigation.

Cutaneous Squamous Cell Carcinoma

CSCC is the second most common skin cancer behind BCC. Previous efforts to characterize the genetic landscape of CSCC have proven difficult given high background mutation rates as a result of ultraviolet damage [9]. UV radiation-induced mutations in TP53 play an important role early in the pathogenesis of CSCC. Mutations in NOTCH1, NOTCH2, CDKN21, HRAS, and FAT1 are also common, while mutations in KMT2C have been associated with poor outcomes and increased bone invasion. Additionally, CSCC displays one of the highest tumor mutational burden (TMB) among all solid tumors and high TMB is associated with increased response to immunotherapy [10].

Advanced CSCC includes both locally advanced CSCC (laCSCC) not amenable to surgery or radiotherapy and metastatic CSCC (mCSCC). For advanced CSCC where a cure is unlikely following surgery or radiotherapy, primary treatment options defined by NCCN CSCC Guidelines Version 1.2024 include neoadjuvant cemiplimab after multidisciplinary discussion and surgical resection utilizing PDEMA or standard excision with wider surgical margins and postoperative margin assessment. For non-surgical candidates, standard of care includes radiotherapy in combination with systemic therapy or systemic therapy alone if curative radiotherapy is not feasible. Guidelines suggest considering neoadjuvant cemiplimab for rapidly growing tumors, in-transit metastasis, lymphovascular invasion, borderline resectability, or if surgery alone may not be curative or may result in significant functional limitations. Preferred systemic regimens include cemiplimab, pembrolizumab, or a clinical trial. In patients who are ineligible for or have progressed on immunotherapy and clinical trials, carboplatin, paclitaxel, and cetuximab may be considered [11].

Chemotherapy and Targeted Therapy

Prior to immunotherapy, both targeted therapy and chemotherapy were used for advanced CSCC with generally poor responses. Epidermal growth factor receptor (EGFR) inhibitors as monotherapy have been associated with an objective response rate (ORR) of 10–31% [12–15]. Data on chemotherapy are limited to retrospective studies or prospective studies with small sample sizes. Although immunotherapy has dramatically changed outcomes for patients, treatment in those with immunotherapy-refractory or ineligible disease still primarily relies upon chemotherapy and/or targeted therapy. In a recent retrospective analysis of patients treated with cetuximab, among 11 patients who were given cetuximab following immunotherapy failure, the ORR was 64% with quick and durable responses, suggesting cetuximab should be considered as the preferred therapy following immunotherapy failure [16].

Immunotherapy

Cemiplimab

Cemiplimab is a monoclonal antibody directed against programmed death 1 (PD-1). In September 2018, the Food and Drug Administration (FDA) approved cemiplimab for treatment of mCSCC or laCSCC in patients who are not candidates for curative surgery or radiation [17]. This marked the first time that the FDA officially approved any systemic therapy for advanced CSCC, for which no standard-of-care existed. Approval was based on a phase I study which included patients with laCSCC and mCSCC as well as a phase II study of patients with mCSCC. In the phase I study, the ORR was 50% while the phase II study reported an ORR of 47% with 4 complete responses (CR) at median follow-up of 7.9 months. Notable adverse events (AE) were cellulitis, pneumonitis, hypercalcemia, pleural effusion, and death [18]. In another study of 78 patients with laCSCC given cemiplimab, the ORR was 44% where 10 patients achieved CR at median follow up of 9.3 months [19]. Another clinical trial investigated fixed-dose cemiplimab compared to weight-based dosing and found an ORR of 45.2% where patients with fixed-dose cemiplimab achieved comparable results to weight-based dosing (ORR of 41.1% vs 49.2%) [20]. EMPOWER-CSCC 1 was the largest pooled dataset of patients with advanced CSCC treated with cemiplimab and reported an ORR of 46.1% at median follow-up of 15.7 months. Additionally, improved CR were observed over time given increased CR in this study as compared with primary analyses as above. Among the 31 complete responders, median time to CR was 11.2 months [21].

Pembrolizumab

Pembrolizumab is another monoclonal antibody targeting PD-1 that became the second immunotherapy agent approved for CSCC in June 2020 for patients with recurrent or mCSCC not curable by surgery or radiation [22]. Later, FDA approval was expanded to include patients with laCSCC not curable by surgery or radiation. Initial approval was based upon data from KEYNOTE-629, a phase II non-randomized study of patients with recurrent or mCSCC. This study also included a cohort of patients with laCSCC. Among patients with recurrent or metastatic disease, the ORR was 35.2%. Among those who responded, 10.5% achieved CR. For patients with laCSCC, the ORR was 50% with 16.7% achieving CR [23]. 69.2% of patients experienced one or more treatment-related AEs. 14 patients discontinued therapy due to AEs and 2 patients died from fatal AEs.

CASKIN was another phase II study of pembrolizumab for advanced CSCC with an ORR of 42% with 4 patients achieving CR and median overall survival was 25.3 months [24].

The I-TACKLE trial (NCT03666325) is a nonrandomized phase 2 trial for patients with laCSCC and mCSCC with pembrolizumab. If patients achieve either a PR or CR, they continued on pembrolizumab. However, in the case of stable disease or disease progression, patients received both pembrolizumab and cetuximab. Thus far, 43 patients have been enrolled and 23 underwent combination treatment (17 PD and 6 SD). 21 patients were noted to have primary resistance and 2 had acquired resistance. Cumulative ORR was 63% with 44% responding to pembrolizumab alone and 38% responding to combination therapy given primary resistance. In the 2 patients with acquired resistance, both achieved PR following combination therapy. Therefore, a total of 44% of patients responded to combination therapy. Combination therapy resulted in one-year PFS of 42% while monotherapy had 51%. Grade ≥ 3 AEs occurred in 35% of patients on combination therapy and 16% of patients on pembrolizumab alone with 3 patients on monotherapy discontinuing treatment secondary to AEs [25].

Nivolumab

Nivolumab is another PD-1 inhibitor being studied for patients with advanced CSCC. A single-arm phase 2 study of nivolumab for systemic treatment-naïve patients with advanced CSCC included 24 patients (4 locally advanced, 16 locoregional, 4 metastatic). Best objective response rate of 58.3% was reported at 24 weeks (0 CR, 14 PR). The incidence of grade 3 or higher immune related adverse events (irAEs) was 25% and only one patient discontinued therapy due to toxicity [26].

Another multicenter, single-arm phase 2 study (NIVOSQUACS) reported impressive results in patients with laCSCC or mCSCC given nivolumab for up to 24 months. Notably, patients with concomitant hematological malignancies (non-progressing or stable under active therapy) were eligible for inclusion and 35% of patients had a coexisting hematological malignancy. The ORR was 61.3% and 22.6% of patients achieved an investigator-assessed complete response. The incidence of grade ≥ 3 irAEs was 19.4% and two patients discontinued nivolumab due to irAEs [27].

Neoadjuvant Use

Neoadjuvant use of cemiplimab has been studied in a phase 2 trial with ORR of 68% in patients with stage II-IV (M0) CSSC and CR in 51%, demonstrating high therapeutic activity in patients with resectable disease [28]. Neoadjuvant therapy allowed for decreased surgical morbidity with preservation of important functional structures. Although not FDA approved since pathologic response rates are not considered a validated endpoint by the FDA, neoadjuvant cemiplimab has become commonplace due to its impressive response rates. It remains unknown if the pathologic response rate translates to improved survival outcomes to support its use as an appropriate surrogate. Despite a lack of long-term outcomes, neoadjuvant cemiplimab has been practice-changing given the potential for reduced surgical morbidity. Since half of all patients develop a complete pathologic response with neoadjuvant cemiplimab, this has resulted in questions about how to best manage sites of disease that are no longer clinically evident and whether definitive interventions of surgery or radiation are necessary. A phase 3 trial evaluating neoadjuvant cemiplimab with survival outcomes is currently under development to determine whether pathologic or clinical response translates to long-term overall survival or progression-free survival benefit.

Several neoadjuvant trials are currently underway assessing use of cemiplimab, pembrolizumab, nivolumab, and nivolumab with ipilimumab for patients with resectable CSCC (Table 1). Case series have reported success with neoadjuvant pembrolizumab in patients with advanced CSCC [29, 30]. Additionally, a trial involving neoadjuvant use of a co-formulated LAG3 inhibitor (favezelimab) plus pembrolizumab (MK-4280A) vs pembrolizumab monotherapy is ongoing (NCT06036836). Neoadjuvant atezolizumab, cetuximab, and erlotinib are also being investigated. Table 1 Ongoing Clinical Trials open to patients with Cutaneous Squamous Cell Carcinoma

Setting	Agent(s)	Population	Phase	NCT identifier	
ADVANCED CSCC—MONOTHERAPY	
	Pembrolizumab	laCSCC, mCSCC	II	NCT02964559	
	Pembrolizumab	laCSCC, mCSCC	II	NCT02721732	
	INCB099280 (small-molecule PD-L1 inhibitor)	advanced CSCC	I	NCT04242199	
	INCB099280 (small-molecule PD-L1 inhibitor)	laCSCC, mCSCC	II	NCT05888844	
	INCB099318 (small molecule PD-L1 inhibitor)	advanced CSCC	I	NCT04272034	
	HLX07 (Recombinant Humanized Anti-EGFR Monoclonal Antibody)	laCSCC, mCSCC	II	NCT05238363	
	Afatinib (tyrosine kinase inhibitor)	laCSCC, mCSCC	II	NCT05070403	
ADVANCED CSCC—COMBINATION	
	Radiotherapy with cemiplimab	laCSCC	II	NCT05574101	
	Anti EGFR antibody-dye conjugate, ASP-1929 with cemiplimab followed by photoimmunotherapy	laCSCC, mCSCC	I/II	NCT04305795	
	OR502 (fully human IgG1 antibody that binds specifically to LILRB2) monotherapy and in combination with cemiplimab	laCSCC, mCSCC	I/II	NCT06090266	
	SAR444245 (pegylated recombinant non-alpha IL2) in combination with cemiplimab	laCSCC, mCSCC	I/II	NCT04913220	
	MK-3475A (pembrolizumab formulated with MK-5180)	laCSCC, mCSCC	II	NCT06041802	
	Cetuximab in combination with pembrolizumab	recurrent and metastatic head and neck CSCC	II	NCT03082534	
	Personalized neoantigen peptide vaccine in combination with pembrolizumab	laCSCC or mCSCC	I	NCT05269381	
	SOT101 monotherapy and in combination with pembrolizumab	laCSCC, mCSCC	I	NCT04234113	
	SOT101 in combination with pembrolizumab	CSCC	II	NCT05256381	
	SGN-B6A monotherapy and in combination with pembrolizumab	laCSCC, mCSCC	I	NCT04389632	
	Vilobelimab (IFX-1, monoclonal anti-C5a antibody) monotherapy and in combination with pembrolizumab	laCSCC, mCSCC	II	NCT04812535	
	Elimusertib (BAY1895344), stereotactic body radiation, and pembrolizumab combination therapy	recurrent head and neck CSCC	I	NCT04576091	
	MDNA11, long-acting "beta-only" recombinant interleukin-2 alone and in combination with pembrolizumab	laCSCC, mCSCC	I/II	NCT05086692	
	BCA101 (targets both EGFR with TGFβ) alone and in combination with pembrolizumab	laCSCC, mCSCC	I	NCT04429542	
	Nivolumab monotherapy and in combination with relatlimab	laCSCC, mCSCC	II	NCT04204837	
	Radiotherapy with atezolizumab	laCSCC, mCSCC	I	NCT05085496	
	NT-I7 (rhIL-7-hyFc) in combination with atezolizumab	laCSCC, mCSCC	I/II	NCT03901573	
	Cobimetinib in combination with atezolizumab	laCSCC, mCSCC	II	NCT03108131	
	Carrilizumab in combination with albumin-binding paclitaxel	laCSCC, mCSCC		NCT05886140	
	Camrelizumab in combination with cisplatin	laCSCC, mCSCC	II	NCT05490485	
	Avelumab monotherapy and in combination with cetuximab	laCSCC, mCSCC	II	NCT03944941	
	GZ17-6.02 monotherapy and in combination with capecitabine	Advanced CSCC	I/II	NCT03775525	
INTRATUMORAL/INTRALESIONAL	
	RP1 monotherapy and in combination with cemiplimab	laCSCC, mCSCC	II	NCT04050436	
	Intratumoral Vidutolimod (CMP-001) in combination with cemiplimab	laCSCC or mCSCC	II	NCT04916002	
	MQ710, a Multi-Transgene Expressing Modified Vaccinia Virus Ankara-Based Virotherapy, monotherapy and in combination with pembrolizumab	CSCC that have failed standard therapy	I	NCT05859074	
	Intratumoral or intravenous TBio-6517, monotherapy and in combination with pembrolizumab	laCSCC or mCSCC that has not received systemic therapy	I/II	NCT04301011	
	TransCon TLR7/8 agonist, monotherapy and in combination with pembrolizumab	laCSCC, mCSCC	I/II	NCT04799054	
	Talimogene Laherparepvec and Nivolumab	Advanced CSCC	II	NCT02978625	
	Talimogene Laherparepvec and Panitumumab	laCSCC, mCSCC	I	NCT04163952	
	Microneedle Array Plus Doxorubicin	resectable stage I-III CSCC	II	NCT05377905	
NEOADJUVANT	
	Cemiplimab	stage II to IV (M0) CSCC	II	NCT04154943	
	Cemiplimab	stage III to stage IV (M0) CSCC of the head/neck, extremity, or trunk, and selected patients with stage II CSCC	I	NCT04975152	
	Cemiplimab	stage II-IV CSCC of the head and neck	II	NCT03565783	
	Cemiplimab	High-risk localized, regionally advanced or locally recurrent CSCC	II	NCT04315701	
	Pembrolizumab	Stage II-IV laCSCC	II	NCT05025813	
	Nivolumab or Nivolumab combined with Ipilimumab	resectable stage III-IVa CSCC	II	NCT04620200	
	Atezolizumab	advanced CSCC	II	NCT04710498	
	Cetuximab	Advanced CSCC		NCT02324608	
	Erlotinib	aggressive resectable CSCC	I	NCT00954226	
NEOADJUVANT + ADJUVANT	
	Cemiplimab	High risk CSCC	I	NCT04428671	
	Cemiplimab	Resectable stage III cutaneous SCC	II	NCT04632433	
	Pembrolizumab	PD-1 naïve high-risk resectable CSCC	II	NCT04808999	
	Coformulated favezelimab/pembrolizumab (MK-4280A) or pembrolizumab	stage II to stage IV resectable laCSCC	II	NCT06036836	
ADJUVANT	
	Cemiplimab	Following surgery and radiation therapy for high risk CSCC	III	NCT03969004	
	Pembrolizumab	Following Surgery and Radiation for high risk laCSCC	III	NCT03833167	
TRANSPLANT	
	Combination of nivolumab and ipilimumab with sirolimus and prednisone	Kidney transplant recipients with laCSCC or mCSCC	I/II	NCT05896839	
	Ruxolitinib	Solid organ transplant recipients with mCSCC	II	NCT04807777	
	RP1 intra-tumoral injection	laCSCC, mCSCC in solid organ transplant recipients or hematopoietic cell transplant	I/II	NCT04349436	

Adjuvant Use

Two trials designed to evaluate adjuvant pembrolizumab (NCT03833167) and cemiplimab (NCT03969004) are underway. In addition, several of the neoadjuvant trials mentioned above include adjuvant use as well. Based on the study designs, it is unclear whether adjuvant therapy is necessary if neoadjuvant therapy is given.

Emerging Therapies

Although survival has improved following approval of immunotherapy, there are many patients with advanced CSCC who do not respond or develop resistance [31–33]. A number of strategies for overcoming immunotherapy resistance are being evaluated, including combination therapies [31–34]. Table 1 summarizes current ongoing trials for the treatment of advanced CSCC.

NCT06090266 is a trial assessing OR502 (IgG antibody that binds to LILRB2) either as monotherapy or in combination with cemiplimab. Pegasus Skin (NCT04913220) is currently investigating SAR444245 (THOR-707, pegylated recombinant IL-2) in combination with cemiplimab. NCT04305795 is a trial assessing combination cemiplimab with ASP-1929 (cetuximab and a light-activated dye) followed by photoimmunotherapy for CSCC. ASP-1929 with pembrolizumab is also being studied for head and neck SCC (HNSCC) with preliminary data showing an ORR of 29.4% [35]. RAMPART (NCT05574101) is a trial evaluating concurrent radiotherapy with cemiplimab. Additionally, a phase 2/3 trial (NCT06295809) evaluating whether personalized neoantigen therapy with novel mRNA vaccine V940 (mRNA-4157) can improve event-free survival in the neoadjuvant/adjuvant setting in combination with pembrolizumab compared to standard of care and pembrolizumab in CSCC has shown promising results in resected high-risk melanoma [36]. NCT06041802 is a trial studying MK-3475A, combination pembrolizumab and MK-5180, a small molecule inhibitor against aurora-A kinase [37]. NCT03082534 is investigating pembrolizumab with cetuximab for HNSCC with preliminary data showing an ORR of 45% at 6 months, exceeding published response rates for pembrolizumab or cetuximab monotherapy in this cohort [34]. NCT05269381 is a phase 1 trial investigating a vaccine targeting neoantigens on tumor cells in combination with pembrolizumab. AURELIO-04 (NCT05256381) is a trial studying SOT101, a subcutaneous IL-15Rβγ agonist in combination with pembrolizumab after phase 1 preliminary data (NCT04234113) showed encouraging results. NCT04389632 is a trial assessing SGN-B6A, an integrin beta-6-targeted antibody–drug conjugate as monotherapy and in combination with pembrolizumab. NCT04812535 is studying vilobelimab (IFX-1), a monoclonal anti-C5a antibody, alone and in combination with pembrolizumab. Vilobelimab has previously been studied in patients with severe sepsis or septic shock given C5a’s role in complement activation [38]. NCT04429542 is studying BCA101, a tumor-targeted bifunctional fusion antibody that simultaneously inhibits EGFR and TGFβ signaling as monotherapy and in combination with pembrolizumab. ABILITY-1 (NCT05086692) is evaluating MDNA11 (long-acting "beta-only" recombinant IL-2) alone and in combination with pembrolizumab. NCT04576091 is investigating combination therapy with elimusertib, a selective oral inhibitor of the Ataxia telangiectasia and Rad3 related kinase, stereotactic body radiation, and pembrolizumab for HNSCC.

Cosibelimab is a monoclonal antibody that binds to PD-L1 with a functional domain capable of inducing antibody-dependent and complement-dependent cytotoxicity against tumor cells [39]. An ORR of 47.4% was reported with a median time to response of 1.9 months and median follow-up of 15.4 months and lower rates of irAEs [39]. Only 23.1% of participants experienced irAEs with 2.5% experiencing grade 3 AEs. In July 2023, long-term data was reported with ORR of 55% for laCSCC (23% CR, 32% PR) and 50% for mCSCC (13% CR, 37% PR) [40]. Given positive results, an application was submitted to the FDA in January 2023 for approval of Cosibelimab for patients with advanced CSCC, however as of December 2023 the medication is not yet approved [41].

The trial arm of NIVOSQUACS (NCT04204837) studying nivolumab combination therapy with relatlimab is ongoing [27]. Relatlimab is a lymphocyte activation gene-3 inhibitor and combination nivolumab-relatlimab is being studied for HNSCC (NCT04326257). Atezolizumab, a monoclonal antibody against PD-L1, is being investigated as combination therapy for CSCC in several ongoing trials: NCT05085496 ( with radiotherapy), NCT03108131 (with cobimetinib), and NCT03901573 (with NT-17[efineptakin alfa], a long-acting IL-7 agonist).

Carrilizumab and camrelizumab are PD-1 inhibitors being studied in combination with chemotherapy: carrilizumab with paclitaxel (NCT05886140) and camrelizumab with cisplatin. NCT03944941 is a trial studying avelumab (a PD-L1 inhibitor) monotherapy and in combination with cetuximab. NCT03775525 is a trial of oral GZ17-6.02 (a combination of isovanillin, curcumin, and harmine) monotherapy and in combination with capecitabine. Afatinib is a tyrosine kinase inhibitor being studied for advanced CSCC (NCT05070403).

Several trials are evaluating oral PD-L1 inhibitors for CSCC (NCT04242199, NCT05888844, NCT04272034). HLX07, a recombinant anti-EGFR monoclonal antibody, is being assessed with preliminary results demonstrating an ORR of 23.8% at 9.6 months and 62.5% at 3.1 months depending on dosage [42].

Talimogene laherparepvec (TVEC) is an oncolytic viral therapy that is FDA approved for advanced melanoma. It has shown success for CSCC and has been explored in several clinical trials (NCT03714828, NCT03458117). T-VEC is also being explored in combination with nivolumab (NCT02978625) for advanced CSCC. Oncolytic viruses have been shown to improve antitumor immune response via multiple mechanisms and are being increasingly studied in clinical trials [43]. Beyond TVEC, a number of oncolytic viruses are currently being investigated both alone and in combination with anti-PD-1 therapies. The CERPASS trial (NCT04050436) is investigating combination cemiplimab and RP1, an oncolytic virus (HSV-1) that expresses a fusogenic glycoprotein and granulocyte macrophage colony stimulating factor. RP1 has shown success in combination with nivolumab for NMSC, including CSCC, in the IGNYTE trial (NCT03767348). NCT05859074 is evaluating MQ710, a multi-transgene expressing modified vaccinia virus, alone and in combination with pembrolizumab. NCT04301011 is investigating intratumoral and intravenous TBio-6517 (an engineered vaccinia virus that expresses the Flt3 ligand, an antibody targeting CTLA4, and IL-12) alone and in combination with pembrolizumab.

Intratumoral vidutolimod is a CpG-A TLR9 agonist that is currently being investigated in combination with cemiplimab (NCT04916002). Finally, a trial assessing intratumoral TransCon TLR7/8 agonist, a sustained-release prodrug of resiquimod, alone and in combination with pembrolizumab is ongoing (NCT04799054).

Basal Cell Carcinoma

Basal cell carcinoma is the most common skin cancer with more than 3.6 million cases diagnosed annually [44]. It is highly correlated to UV exposure and skin type [1, 45, 46]. It is more common in older adults due to cumulative UV exposure but has been increasing in incidence for younger adults as well, which may be partially explained by artificial UV sources [47]. The cause of basal cell carcinoma is complex and multifactorial, including genetics (such as mutations in the Hedgehog signaling pathway), phenotype (lighter skin color), and environment (UV exposure).

For laBCC not amenable to curative intent local intervention, the current standard of care is initial treatment with a hedgehog inhibitor (HHI) (either vismodegib or sonidegib). For mBCC, vismodegib is the initial HHI of choice. Alternative dosing schedules or drug holidays can be used for intolerable side effects. For patients who were previously treated with a HHI or who cannot tolerate an HHI, cemiplimab is the standard second-line therapy.

Hedgehog Inhibitors

70% of sporadic BCCs have PTCH1 (protein patched homolog 1) mutations, the receptor for Sonic Hedgehog (Shh) [48]. When Shh binds PTCH1, smoothened (SMO), an associated protein suppressed by unbound PTCH1, loses this inhibition and becomes activated, leading to cell proliferation [49]. Inactivating mutations in PTCH1 or activating mutations in SMO are both commonly found in BCC. Indeed, inherited mutations in PTCH1 lead to Gorlin Syndrome (nevoid basal-cell carcinoma syndrome), a condition associated with development of multiple BCCs, particularly at a young age [50]. Attempts to target the PTCH1/Shh/SMO pathway led to the development of Hedgehog pathway inhibitors [51].

Vismodegib was the first oral SMO inhibitor developed to target this pathway. It was FDA approved in January 2012 for treatment of locally advanced (laBCC) or metastatic BCC (mBCC) based on results of the ERIVANCE BCC trial [52]. In this trial, ORR was 30% in patients with mBCC and 43% in patients with laBCC. The median progression free survival (PFS) for mBCC was 9.2 months and 9.5 months for laBCC. 25% of patients developed grade III-IV adverse effects, with muscle spasms, alopecia, weight loss, and dysgeusia being the most common. Meta-analyses have found similar results with an average ORR of 64.7% for laBCC and 33.6% for mBCC. Patients were on vismodegib for an average of 35.8 weeks [53]. In this analysis, 28.2% of patients discontinued vismodegib due to adverse effects, with muscle spasms, dysgeusia, and alopecia being the most common effects noted.

Due to the durable effects of vismodegib in cases where surgical resection was not amenable, vismodegib was studied in the neoadjuvant setting in patients with laBCC with the goal of tumor shrinkage prior to surgical resection. Large tumor size may render certain patients inoperable or have significant morbidities associated with resection such as functional deficits or disfiguration. In the VISMONEO trial, 80% of patients with locally advanced BCC who received neoadjuvant vismodegib achieved downstaging of surgical resection after a mean treatment duration of 6 months [54]. 36% of patients had known recurrence at 3 years of follow-up. There was a 20% incidence of grade III-IV adverse effects. Neoadjuvant use of vismodegib has also been studied in the use of periocular laBCC where it had an ORR of 75% and reduced rates of orbital exenteration (surgical removal of the eyeball and surrounding tissues) from 46 to 6% [55, 56].

Sonidegib is another oral SMO inhibitor that is currently approved for laBCC. In the BOLT trial, the ORR (while on 200mg) for mBCC was 8% and 56% for laBCC. Median PFS was 13.1 months for mBCC and 22.1 months for laBCC. There was a 43% incidence of grade 3–4 adverse effects with a side effect profile comparable to vismodegib. There have been no head-to-head trials comparing vismodegib to sonidegib [57]. In an indirect comparison, sonidegib had a higher ORR and PFS compared to vismodegib with slightly lower rates of adverse effects [58, 59].

Adverse effects are a limiting factor in the long-term tolerability of HHIs for patients. In addition, these adverse effects are class-specific, meaning that sonidegib and vismodegib will be tolerated similarly for a specific patient and switching agents due to adverse effects will likely not lead to better tolerability [60]. As a result, altering the drug-regimen schedule in response to adverse effects has become protocolized with similar efficacy as seen in the original clinical trials [61, 62].

Tadadegib is a new HHI currently under investigation. Phase I data showed an appropriate safety profile and clinical response but there are not currently any active phase II trials [63]. Clinical trials of topical hedgehog inhibitors (patidegib) in order to minimize systemic absorption and adverse effects are currently under investigation [64]. Interestingly, itraconazole, an antifungal medication, is a strong antagonist of the Hedgehog inhibitor pathway, in a mechanism different from oral SMO inhibitors, and is also being studied in the treatment of BCC [65].

Patients on HHIs can develop resistance during treatment, leading to refractory disease. Analyses have shown that most cases of HHI resistance are due to mutations of SMO that lead to alterations in how the drug accesses its binding site or mutations in the binding site itself. There are also downstream targets that have been found to have mutations, conferring resistance [66, 67].

Immunotherapy

Cemiplimab was approved in February 2021 for treatment of laBCC in patients who already progressed through or were intolerant to HHIs. In long-term follow-up of NCT03132636, there was an ORR of 32.1% with a median PFS of 15.6 months. 48% of patients suffered grade III-IV adverse events [68, 69]. There have been case series of other immunotherapy agents, such as pembrolizumab, given with and without oral SMO agents with similar effectiveness (44% ORR for pembrolizumab alone and 29% for combination therapy) [70].

Merkel Cell Carcinoma

Merkel cell carcinoma is a rare and aggressive skin cancer that has neuroendocrine features. It is neuroendocrine in origin due to immunohistochemistry revealing chromogranin A, synaptophysin, and CD56, as well as somatostatin receptors [71, 72]. Despite the tumor cell’s resemblance to Merkel cells which are mechanoreceptors in the dermis of the skin, it is currently believed that MCC does not arise from Merkel cells and the true origin has yet to be elucidated [73]. 80% of cases of MCC are thought to be due to the Merkel cell polyomavirus (MCV) and cases not associated with MCV are thought to be due to DNA damage from UV radiation [74, 75].

For mMCC, standard therapy includes anti PD-1 therapy (avelumab, pembrolizumab, nivolumab, or retifanlimab). Avelumab or pembrolizumab are most used due to their prevalence.

Cytotoxic Chemotherapy

Before the advent of immunotherapy, cytotoxic chemotherapy was used as first-line for patients with metastatic MCC (mMCC). While multiple different regimens were used, the most common were etoposide with either carboplatin or cisplatin [76]. 55% of patients responded to first-line chemotherapy and 23% of patients responded to second-line therapy with a median overall survival of 9.5 months from the start of chemotherapy.

Cytotoxic chemotherapy is still used for patients who have progressed through or who cannot tolerate immunotherapy and is also used for palliative debulking and symptomatic management [77]. There have been studies investigating if adjuvant use of systemic chemotherapy after surgery or radiation improves survival and, so far, no survival benefit has been seen [78, 79].

Immunotherapy

PD-L1 expression was found in the MCC microenvironment in 49% of tumor cells, making it a possible target in the treatment of mMCC [80]. Avelumab (PD-L1 inhibitor) became the first FDA-approved agent for the treatment of mMCC in 2017 [81]. Evidence for this use came out of the results of the JAVELIN Merkel 200 trial which showed ORR of 33% and median PFS of 2.7 months in patients with mMCC who had progressed on cytotoxic chemotherapy [82, 83]. Only 10% of patients had grade III-IV adverse effects. There was a trend towards a lower ORR for patients with MCV-positive versus MCV-negative tumors (26% versus 46%) but the results were not statistically significant. In comparison, patients with mMCC who were chemotherapy-naïve were shown to have a higher ORR (56.3% versus 33%) [84].

Pembrolizumab was approved for mMCC in 2018. In the KEYNOTE-017 trial, patients with mMCC who were chemotherapy-naïve had an ORR of 56% with a median PFS of 16.8 months [85]. The response rate was higher among those with MCV-positive tumors than those with MCV-negative tumors (62% versus 44%). 28% of patients had grade III-IV adverse effects. An extended analysis with a median follow-up of 31.8 months showed an overall response rate of 58% [86]. There have been no head-to-head comparisons of avelumab versus pembrolizumab.

Retifanlimab is another PD-1 inhibitor approved for advanced or metastatic MCC. The POD1UM-201 trial showed an ORR of 46.2% among chemotherapy-naïve patients with 28.7% of patients having grade III-IV adverse effects [87]. Nivolumab has been studied in the neoadjuvant setting for MCC. In the CheckMate 358 trial, 47% of patients with resectable MCC who received neoadjuvant nivolumab achieved a pathologic complete response after surgery and 54.5% had tumor reduction of 30% or greater with a median follow-up of 26 weeks [88]. 7.7% of patients had grade III-IV adverse effects. Given the availability of durable responses both avelumab and pembrolizumab have shown and limited long-term data with retifanlimab or nivolumab, these two agents are not commonly used.

Combination immune-checkpoint inhibitors (ipilimumab and nivolumab) have also been studied for advanced MCC. Patients who were immunotherapy-naïve had an ORR of 100% while patients who had been previously treated with immunotherapy had an overall response rate of 31%, with higher toxicity profiles than patients on single immunotherapy agents alone [89] In another study looking at combination therapy for patients who progressed on single agents, 31% of patients experienced a grade III-IV immune-related adverse event with a median overall survival of 4.7 months from the initiation of combination therapy [90]. As a result of a high toxicity profile and conflicting data on whether or not combination therapy provides improved responses to single therapy alone, combination therapy is only recommended for use in patients who have progressed on single therapy [89–93].

Adjuvant nivolumab has been studied after complete resection of MCC in the ADMEC-O trial. Nivolumab was found to have an absolute risk reduction of 10% of disease-free survival versus observation (84% versus 73%) with 42% of patients treated with nivolumab having grade 3–4 adverse events versus 11% of patients under observation [94].

Emerging Therapies

Like other neuroendocrine tumors, MCC expresses somatostatin receptors, activation of which generally triggers inhibitory pathways downstream. The use of somatostatin analogues in the treatment of mMCC has been studied in case series with some success [95, 96]. Currently, there are clinical trials ongoing looking at the use of peptide receptor radionuclide therapy in combination with immunotherapy for mMCC, which has already shown success in small case series [97, 98].

T-VEC has shown some success in case reports when used for advanced MCC [99, 100]. It is currently being investigated in clinical trials [101].

Many other clinical trials are ongoing. The MERCURY trial is looking at neoadjuvant retifanlimab plus platinum-etoposide therapy for resectable MCC (NCT05594290) [102]. The I-MAT trial is a phase II trial investigating adjuvant avelumab in stage I-III MCC (NCT04291885) [103] The ADAM trial is a phase III trial investigating adjuvant avelumab in stage III MCC (NCT03271372) [104]. The KEYNOTE-913 trial is a phase III study looking at pembrolizumab in untreated advanced MCC (NCT03783078) [105]. The MERKLIN2 trial is a phase II study investigating domatinostat, a histone deacetylase inhibitor, in combination with avelumab in patients with advanced or metastatic MCC who have progressed on anti-PD-L1 therapy (NCT04393753) [106]. NCT03787602 is a study investigating KRT-232, a MDM2 inhibitor, for MCC in patients who failed treatment with anti-PD-1 or anti-PD-L1 therapy [107].

Transplant Patients

Immunocompromised patients have a higher risk of developing CSCC with studies suggesting poorer outcomes [108]. It has been shown that cost of skin-cancer related dermatological care for transplant recipients is higher when compared with non-immunosuppressed patients, which is primarily driven by CSCCs in transplant patients requiring advanced and/or multimodal treatment regimens [109].

Among solid organ transplant recipients (SOTRs), risk of rejection is notable with one study reporting it to be as high as 37% [108]. Several clinical trials are exploring safety and efficacy of immunotherapy for SOTR with advanced skin cancer. CONTRAC-1 (NCT04339062) reported results of a phase I study of cemiplimab for renal transplant recipients with advanced CSCC [110]. Twelve patients received cemiplimab with a standardized approach to immunosuppression with mTOR inhibition and dynamic prednisone. Of 11 evaluable patients, 5 responded at median follow-up of 6.8 months (3 CR and 2 PR), no patients experienced rejection or graft loss [111]. Two patient had stable disease. One patient died of angioedema and anaphylaxis which was attributed to the mTOR inhibitor [110]. NCT03816332 is a phase I/II trial assessing combination nivolumab plus tacrolimus plus prednisone ± ipilimumab in renal transplant patients with advanced skin cancers, including 5 patients with CSCC and 2 with MCC [112]. All patients had progressive disease with nivolumab + tacrolimus + prednisone. For those with CSCC, 3 patients received nivolumab + tacrolimus + prednisone + ipilimumab resulting in 2 CR and 1 stable disease. One of the patients with CR experienced treatment-related allograft loss 6 weeks after starting nivolumab. Both patients with MCC were subsequently treated with addition of ipilimumab however both had progressive disease and one experienced allograft loss 8 weeks after discontinuation of therapy [112]. Thus, the risk of rejection must be clearly discussed with transplant patients being considered for immunotherapy and patients should be evaluated on a case-by-case basis pending future studies. Immunosuppression with mTOR inhibition and a pulsed steroid approach for transplant patients on immunotherapy may be considered.

Conclusion

In this review, we examined the latest advances of systemic therapies for advanced and metastatic non-melanoma skin cancers. Understanding the pathophysiology and molecular background of NMSC has become increasingly essential as more and more targeted therapies are being developed and studied. Immunotherapy has greatly expanded treatment options across all types of NMSC and its use in both neoadjuvant and adjuvant settings are actively being investigated. As the incidence of non-melanoma skin cancer continues to rise, clinicians should feel better equipped to treat advanced and metastatic NMSC.

Author contributions

SL and KAO wrote the main manuscript text. KAO prepared tables. JC supervised the project and contributed to the final version of the manuscript.

Data Availability

No datasets were generated or analysed during the current study.

Declarations

Competing interests

The authors declare no competing interests.

Conflict of Interest

Spencer Lessans and Katie O’Connell declare no conflict of interest. Jennifer Choe has served on scientific advisory boards and/or receives institutional research funding for Merck Sharpe & Dohme, Regeneron, Coherus Biosciences, Eisei, and Exelixis.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Spencer Lessans and Katie A. O’Connell are the co-first authors.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Rogers HW Weinstock MA Feldman SR Coldiron BM Incidence estimate of nonmelanoma skin cancer (Keratinocyte Carcinomas) in the US Population, 2012 JAMA Dermatol 2015 151 1081 10.1001/jamadermatol.2015.1187 25928283
Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence estimate of nonmelanoma skin cancer (Keratinocyte Carcinomas) in the US Population, 2012. JAMA Dermatol. 2015;151:1081. 10.1001/jamadermatol.2015.1187.25928283
2. Diffey BL Langtry JAA Skin cancer incidence and the ageing population: Correspondence Br J Dermatol 2005 153 679 680 10.1111/j.1365-2133.2005.06799.x 16120172
Diffey BL, Langtry JAA. Skin cancer incidence and the ageing population: Correspondence. Br J Dermatol. 2005;153:679–80. 10.1111/j.1365-2133.2005.06799.x.16120172
3. Global Burden of Disease Cancer CollaborationFitzmaurice C Abate D Abbasi N Abbastabar H Abd-Allah F Global, Regional, and National cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study JAMA Oncol 2019 5 1749 10.1001/jamaoncol.2019.2996 31560378
Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, et al. Global, Regional, and National cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. JAMA Oncol. 2019;5:1749. 10.1001/jamaoncol.2019.2996.31560378
4. Ciążyńska M Kamińska-Winciorek G Lange D Lewandowski B Reich A Sławińska M The incidence and clinical analysis of non-melanoma skin cancer Sci Rep 2021 11 4337 10.1038/s41598-021-83502-8 33619293
Ciążyńska M, Kamińska-Winciorek G, Lange D, Lewandowski B, Reich A, Sławińska M, et al. The incidence and clinical analysis of non-melanoma skin cancer. Sci Rep. 2021;11:4337. 10.1038/s41598-021-83502-8.33619293
5. Kim I He Y-Y Ultraviolet radiation-induced non-melanoma skin cancer: Regulation of DNA damage repair and inflammation Genes Dis 2014 1 188 198 10.1016/j.gendis.2014.08.005 25642450
Kim I, He Y-Y. Ultraviolet radiation-induced non-melanoma skin cancer: Regulation of DNA damage repair and inflammation. Genes Dis. 2014;1:188–98. 10.1016/j.gendis.2014.08.005.25642450
6. Fahradyan A Howell A Wolfswinkel E Tsuha M Sheth P Wong A Updates on the Management of Non-Melanoma Skin Cancer (NMSC) Healthcare 2017 5 82 10.3390/healthcare5040082 29104226
Fahradyan A, Howell A, Wolfswinkel E, Tsuha M, Sheth P, Wong A. Updates on the Management of Non-Melanoma Skin Cancer (NMSC). Healthcare. 2017;5:82. 10.3390/healthcare5040082.29104226
7. Tanese K Nakamura Y Hirai I Funakoshi T Updates on the systemic treatment of advanced non-melanoma skin cancer Front Med 2019 6 160 10.3389/fmed.2019.00160
Tanese K, Nakamura Y, Hirai I, Funakoshi T. Updates on the systemic treatment of advanced non-melanoma skin cancer. Front Med. 2019;6:160. 10.3389/fmed.2019.00160.
8. Hodi FS O’Day SJ McDermott DF Weber RW Sosman JA Haanen JB Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 2010 363 711 723 10.1056/NEJMoa1003466 20525992
Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23. 10.1056/NEJMoa1003466.20525992
9. Pickering CR Zhou JH Lee JJ Drummond JA Peng SA Saade RE Mutational landscape of aggressive cutaneous squamous cell carcinoma Clin Cancer Res 2014 20 6582 6592 10.1158/1078-0432.CCR-14-1768 25303977
Pickering CR, Zhou JH, Lee JJ, Drummond JA, Peng SA, Saade RE, et al. Mutational landscape of aggressive cutaneous squamous cell carcinoma. Clin Cancer Res. 2014;20:6582–92. 10.1158/1078-0432.CCR-14-1768.25303977
10. Ascierto PA Schadendorf D Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma J Immunother Cancer 2022 10 e005082 10.1136/jitc-2022-005082 36455990
Ascierto PA, Schadendorf D. Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma. J Immunother Cancer. 2022;10:e005082. 10.1136/jitc-2022-005082.36455990
11. National Comprehensive Cancer Network. Squamous Cell Skin Cancer (Version 1.2024). [Internet]. [updated 2023; cited 2024 Jan 2]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/squamous.pdf.
12. William WN Feng L Ferrarotto R Ginsberg L Kies M Lippman S Gefitinib for patients with incurable cutaneous squamous cell carcinoma: A single-arm phase II clinical trial J Am Acad Dermatol 2017 77 1110 1113.e2 10.1016/j.jaad.2017.07.048 28964539
William WN, Feng L, Ferrarotto R, Ginsberg L, Kies M, Lippman S, et al. Gefitinib for patients with incurable cutaneous squamous cell carcinoma: A single-arm phase II clinical trial. J Am Acad Dermatol. 2017;77:1110-1113.e2. 10.1016/j.jaad.2017.07.048.28964539
13. Maubec E Petrow P Scheer-Senyarich I Duvillard P Lacroix L Gelly J Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin J Clin Oncol 2011 29 3419 3426 10.1200/JCO.2010.34.1735 21810686
Maubec E, Petrow P, Scheer-Senyarich I, Duvillard P, Lacroix L, Gelly J, et al. Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin. J Clin Oncol. 2011;29:3419–26. 10.1200/JCO.2010.34.1735.21810686
14. Gold KA Kies MS William WN Johnson FM Lee JJ Glisson BS Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial Cancer 2018 124 2169 2173 10.1002/cncr.31346 29579331
Gold KA, Kies MS, William WN, Johnson FM, Lee JJ, Glisson BS. Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial. Cancer. 2018;124:2169–73. 10.1002/cncr.31346.29579331
15. Foote MC McGrath M Guminski A Hughes BGM Meakin J Thomson D Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma Ann Oncol 2014 25 2047 2052 10.1093/annonc/mdu368 25091317
Foote MC, McGrath M, Guminski A, Hughes BGM, Meakin J, Thomson D, et al. Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma. Ann Oncol. 2014;25:2047–52. 10.1093/annonc/mdu368.25091317
16. Marin-Acevedo JA Withycombe BM Kim Y Brohl AS Eroglu Z Markowitz J Cetuximab for immunotherapy-refractory/ineligible cutaneous squamous cell carcinoma Cancers 2023 15 3180 10.3390/cancers15123180 37370790
Marin-Acevedo JA, Withycombe BM, Kim Y, Brohl AS, Eroglu Z, Markowitz J, et al. Cetuximab for immunotherapy-refractory/ineligible cutaneous squamous cell carcinoma. Cancers. 2023;15:3180. 10.3390/cancers15123180.37370790
17. Food and Drug Administration. FDA approves first treatment for advanced form of the second most common skin cancer. 2018. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-advanced-form-second-most-common-skin-cancer-0. Accessed 5 Dec 2023.
18. Migden MR Rischin D Schmults CD Guminski A Hauschild A Lewis KD PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma N Engl J Med 2018 379 341 351 10.1056/NEJMoa1805131 29863979
Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379:341–51. 10.1056/NEJMoa1805131.29863979
19. Migden MR Khushalani NI Chang ALS Lewis KD Schmults CD Hernandez-Aya L Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial Lancet Oncol 2020 21 294 305 10.1016/S1470-2045(19)30728-4 31952975
Migden MR, Khushalani NI, Chang ALS, Lewis KD, Schmults CD, Hernandez-Aya L, et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol. 2020;21:294–305. 10.1016/S1470-2045(19)30728-4.31952975
20. Rischin D Migden MR Lim AM Schmults CD Khushalani NI Hughes BGM Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing J Immunother Cancer 2020 8 e000775 10.1136/jitc-2020-000775 32554615
Rischin D, Migden MR, Lim AM, Schmults CD, Khushalani NI, Hughes BGM, et al. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. J Immunother Cancer. 2020;8:e000775. 10.1136/jitc-2020-000775.32554615
21. Rischin D Khushalani NI Schmults CD Guminski A Chang ALS Lewis KD Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis J Immunother Cancer 2021 9 e002757 10.1136/jitc-2021-002757 34413166
Rischin D, Khushalani NI, Schmults CD, Guminski A, Chang ALS, Lewis KD, et al. Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis. J Immunother Cancer. 2021;9:e002757. 10.1136/jitc-2021-002757.34413166
22. Food and Drug Administration. FDA approves pembrolizumab for cutaneous squamous cell carcinoma. 2020. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-cutaneous-squamous-cell-carcinoma. Accessed 5 Dec 2023.
23. Hughes BGM Munoz-Couselo E Mortier L Bratland Å Gutzmer R Roshdy O Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial Ann Oncol 2021 32 1276 1285 10.1016/j.annonc.2021.07.008 34293460
Hughes BGM, Munoz-Couselo E, Mortier L, Bratland Å, Gutzmer R, Roshdy O, et al. Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial. Ann Oncol. 2021;32:1276–85. 10.1016/j.annonc.2021.07.008.34293460
24. Maubec E Boubaya M Petrow P Beylot-Barry M Basset-Seguin N Deschamps L Phase II study of pembrolizumab as first-line, single-drug therapy for patients with unresectable cutaneous squamous cell carcinomas J Clin Oncol 2020 38 3051 3061 10.1200/JCO.19.03357 32730186
Maubec E, Boubaya M, Petrow P, Beylot-Barry M, Basset-Seguin N, Deschamps L, et al. Phase II study of pembrolizumab as first-line, single-drug therapy for patients with unresectable cutaneous squamous cell carcinomas. J Clin Oncol. 2020;38:3051–61. 10.1200/JCO.19.03357.32730186
25. Bossi P Alberti A Bergamini C Resteghini C Locati LD Alfieri S Immunotherapy followed by cetuximab in locally advanced/metastatic (LA/M) cutaneous squamous cell carcinomas (cSCC): The I-TACKLE trial J Clin Oncol 2022 40 9520 9520 10.1200/JCO.2022.40.16_suppl.9520
Bossi P, Alberti A, Bergamini C, Resteghini C, Locati LD, Alfieri S, et al. Immunotherapy followed by cetuximab in locally advanced/metastatic (LA/M) cutaneous squamous cell carcinomas (cSCC): The I-TACKLE trial. J Clin Oncol. 2022;40:9520–9520. 10.1200/JCO.2022.40.16_suppl.9520.
26. Munhoz RR Nader-Marta G De Camargo VP Queiroz MM Cury-Martins J Ricci H A phase 2 study of first-line nivolumab in patients with locally advanced or metastatic cutaneous squamous-cell carcinoma Cancer 2022 128 4223 4231 10.1002/cncr.34463 36274573
Munhoz RR, Nader-Marta G, De Camargo VP, Queiroz MM, Cury-Martins J, Ricci H, et al. A phase 2 study of first-line nivolumab in patients with locally advanced or metastatic cutaneous squamous-cell carcinoma. Cancer. 2022;128:4223–31. 10.1002/cncr.34463.36274573
27. Lang R Welponer T Richtig E Wolf I Hoeller C Hafner C Nivolumab for locally advanced and metastatic cutaneous squamous cell carcinoma ( NIVOSQUACS study)—Phase II data covering impact of concomitant haematological malignancies J Eur Acad Dermatol Venereol 2023 37 1799 1810 10.1111/jdv.19218 37210651
Lang R, Welponer T, Richtig E, Wolf I, Hoeller C, Hafner C, et al. Nivolumab for locally advanced and metastatic cutaneous squamous cell carcinoma ( NIVOSQUACS study)—Phase II data covering impact of concomitant haematological malignancies. J Eur Acad Dermatol Venereol. 2023;37:1799–810. 10.1111/jdv.19218.37210651
28. Gross ND Miller DM Khushalani NI Divi V Ruiz ES Lipson EJ Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma N Engl J Med 2022 387 1557 1568 10.1056/NEJMoa2209813 36094839
Gross ND, Miller DM, Khushalani NI, Divi V, Ruiz ES, Lipson EJ, et al. Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma. N Engl J Med. 2022;387:1557–68. 10.1056/NEJMoa2209813.36094839
29. Blaise M, Poissonnet G, Cardot‐Leccia N, Sudaka A, Velin M, Chassang M, et al. Pathological complete response to neoadjuvant pembrolizumab in a patient with metastatic cutaneous squamous cell carcinoma. J Eur Acad Dermatol Venereol. 2023;37. 10.1111/jdv.19307.
30. Goldfarb JA Ferrarotto R Gross N Goepfert R Debnam JM Gunn B Immune checkpoint inhibitors for treatment of periorbital squamous cell carcinoma Br J Ophthalmol 2023 107 320 323 10.1136/bjophthalmol-2021-319417 34625433
Goldfarb JA, Ferrarotto R, Gross N, Goepfert R, Debnam JM, Gunn B, et al. Immune checkpoint inhibitors for treatment of periorbital squamous cell carcinoma. Br J Ophthalmol. 2023;107:320–3. 10.1136/bjophthalmol-2021-319417.34625433
31. García-Sancha N Corchado-Cobos R Bellido-Hernández L Román-Curto C Cardeñoso-Álvarez E Pérez-Losada J Overcoming resistance to immunotherapy in advanced cutaneous squamous cell carcinoma Cancers 2021 13 5134 10.3390/cancers13205134 34680282
García-Sancha N, Corchado-Cobos R, Bellido-Hernández L, Román-Curto C, Cardeñoso-Álvarez E, Pérez-Losada J, et al. Overcoming resistance to immunotherapy in advanced cutaneous squamous cell carcinoma. Cancers. 2021;13:5134. 10.3390/cancers13205134.34680282
32. Silk AW Barker CA Bhatia S Bollin KB Chandra S Eroglu Z Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer J Immunother Cancer 2022 10 e004434 10.1136/jitc-2021-004434 35902131
Silk AW, Barker CA, Bhatia S, Bollin KB, Chandra S, Eroglu Z, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer. J Immunother Cancer. 2022;10:e004434. 10.1136/jitc-2021-004434.35902131
33. Alberti A Bossi P Immunotherapy for cutaneous squamous cell carcinoma: results and perspectives Front Oncol 2022 11 727027 10.3389/fonc.2021.727027 35070956
Alberti A, Bossi P. Immunotherapy for cutaneous squamous cell carcinoma: results and perspectives. Front Oncol. 2022;11:727027. 10.3389/fonc.2021.727027.35070956
34. Sacco AG Chen R Worden FP Wong DJL Adkins D Swiecicki P Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial Lancet Oncol 2021 22 883 892 10.1016/S1470-2045(21)00136-4 33989559
Sacco AG, Chen R, Worden FP, Wong DJL, Adkins D, Swiecicki P, et al. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. Lancet Oncol. 2021;22:883–92. 10.1016/S1470-2045(21)00136-4.33989559
35. Cognetti DM Recent safety and efficacy findings from a phase 1b/2 open-label combination study of ASP-1929 photoimmunotherapy with anti-PD-1 therapy in EGFR-expressing advanced head and neck squamous cell carcinoma (HNSCC) JCO 2024 42 6083 6083 10.1200/JCO.2024.42.16_suppl.6083
Cognetti DM, et al. Recent safety and efficacy findings from a phase 1b/2 open-label combination study of ASP-1929 photoimmunotherapy with anti-PD-1 therapy in EGFR-expressing advanced head and neck squamous cell carcinoma (HNSCC). JCO. 2024;42:6083–6083. 10.1200/JCO.2024.42.16_suppl.6083.
36. Weber JS Carlino MS Khattak A Meniawy T Ansstas G Taylor MH Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study Lancet 2024 403 632 644 10.1016/S0140-6736(23)02268-7 38246194
Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2024;403:632–44. 10.1016/S0140-6736(23)02268-7.38246194
37. Amin M Minton SE LoRusso PM Krishnamurthi SS Pickett CA Lunceford J A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors Invest New Drugs 2016 34 84 95 10.1007/s10637-015-0306-7 26620496
Amin M, Minton SE, LoRusso PM, Krishnamurthi SS, Pickett CA, Lunceford J, et al. A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors. Invest New Drugs. 2016;34:84–95. 10.1007/s10637-015-0306-7.26620496
38. Bauer M Weyland A Marx G Bloos F Weber S Weiler N Efficacy and safety of Vilobelimab (IFX-1), a novel monoclonal anti-C5a antibody, in patients with early severe sepsis or septic shock—a randomized, placebo-controlled, double-blind, multicenter, phase IIa trial (SCIENS Study) Crit Care Explor 2021 3 e0577 10.1097/CCE.0000000000000577 34806021
Bauer M, Weyland A, Marx G, Bloos F, Weber S, Weiler N, et al. Efficacy and safety of Vilobelimab (IFX-1), a novel monoclonal anti-C5a antibody, in patients with early severe sepsis or septic shock—a randomized, placebo-controlled, double-blind, multicenter, phase IIa trial (SCIENS Study). Crit Care Explor. 2021;3:e0577. 10.1097/CCE.0000000000000577.34806021
39. Clingan P Ladwa R Brungs D Harris DL McGrath M Arnold S Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma J Immunother Cancer 2023 11 e007637 10.1136/jitc-2023-007637 37848259
Clingan P, Ladwa R, Brungs D, Harris DL, McGrath M, Arnold S, et al. Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma. J Immunother Cancer. 2023;11:e007637. 10.1136/jitc-2023-007637.37848259
40. Checkpoint Therapeutics. Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results Demonstrating Substantial Increases in Complete Response Rates in Advanced Cutaneous Squamous Cell Carcinoma. Checkp Ther. 2023. https://ir.checkpointtx.com/news-events/press-releases/detail/102/checkpoint-therapeutics-announces-cosibelimab-longer-term. Accessed 20 Dec 2023.
41. Sava J. FDA Issues CRL to Cosibelimab in Metastatic or Locally Advanced CSCC. 2023. https://www.targetedonc.com/view/fda-issues-crl-to-cosibelimab-in-metastatic-or-locally-advanced-cscc. Accessed 5 June 2024.
42. Li C Zhu D Fan Z Chen Y Chen Y Li Y 86P Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study Ann Oncol 2023 34 S1500 10.1016/j.annonc.2023.10.221
Li C, Zhu D, Fan Z, Chen Y, Chen Y, Li Y, et al. 86P Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study. Ann Oncol. 2023;34:S1500. 10.1016/j.annonc.2023.10.221.
43. Yun C-O Hong J Yoon A-R Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements Front Immunol 2022 13 953410 10.3389/fimmu.2022.953410 36091031
Yun C-O, Hong J, Yoon A-R. Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements. Front Immunol. 2022;13:953410. 10.3389/fimmu.2022.953410.36091031
44. Skin Cancer Foundation. Our New Approach to a Challenging Skin Cancer Statistic. 2021. https://www.skincancer.org/blog/our-new-approach-to-a-challenging-skin-cancer-statistic/. Accessed 20 Dec 2023.
45. Teng Y Yu Y Li S Huang Y Xu D Tao X Ultraviolet radiation and basal cell carcinoma: an environmental perspective Front Public Health 2021 9 666528 10.3389/fpubh.2021.666528 34368047
Teng Y, Yu Y, Li S, Huang Y, Xu D, Tao X, et al. Ultraviolet radiation and basal cell carcinoma: an environmental perspective. Front Public Health. 2021;9:666528. 10.3389/fpubh.2021.666528.34368047
46. Verkouteren JAC Ramdas KHR Wakkee M Nijsten T Epidemiology of basal cell carcinoma: scholarly review Br J Dermatol 2017 177 359 372 10.1111/bjd.15321 28220485
Verkouteren JAC, Ramdas KHR, Wakkee M, Nijsten T. Epidemiology of basal cell carcinoma: scholarly review. Br J Dermatol. 2017;177:359–72. 10.1111/bjd.15321.28220485
47. Christenson LJ Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years JAMA 2005 294 681 10.1001/jama.294.6.681 16091570
Christenson LJ. Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA. 2005;294:681. 10.1001/jama.294.6.681.16091570
48. Pellegrini C Maturo M Di Nardo L Ciciarelli V Gutiérrez García-Rodrigo C Fargnoli M Understanding the molecular genetics of basal cell carcinoma Int J Mol Sci 2017 18 2485 10.3390/ijms18112485 29165358
Pellegrini C, Maturo M, Di Nardo L, Ciciarelli V, Gutiérrez García-Rodrigo C, Fargnoli M. Understanding the molecular genetics of basal cell carcinoma. Int J Mol Sci. 2017;18:2485. 10.3390/ijms18112485.29165358
49. Arensdorf AM Marada S Ogden SK Smoothened regulation: a tale of two signals Trends Pharmacol Sci 2016 37 62 72 10.1016/j.tips.2015.09.001 26432668
Arensdorf AM, Marada S, Ogden SK. Smoothened regulation: a tale of two signals. Trends Pharmacol Sci. 2016;37:62–72. 10.1016/j.tips.2015.09.001.26432668
50. Tang JY Mackay-Wiggan JM Aszterbaum M Yauch RL Lindgren J Chang K Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome N Engl J Med 2012 366 2180 2188 10.1056/NEJMoa1113538 22670904
Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012;366:2180–8. 10.1056/NEJMoa1113538.22670904
51. Von Hoff DD LoRusso PM Rudin CM Reddy JC Yauch RL Tibes R Inhibition of the hedgehog pathway in advanced basal-cell carcinoma N Engl J Med 2009 361 1164 1172 10.1056/NEJMoa0905360 19726763
Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009;361:1164–72. 10.1056/NEJMoa0905360.19726763
52. Sekulic A Migden MR Oro AE Dirix L Lewis KD Hainsworth JD Efficacy and safety of vismodegib in advanced basal-cell carcinoma N Engl J Med 2012 366 2171 2179 10.1056/NEJMoa1113713 22670903
Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366:2171–9. 10.1056/NEJMoa1113713.22670903
53. Jacobsen AA Aldahan AS Hughes OB Shah VV Strasswimmer J Hedgehog pathway inhibitor therapy for locally advanced and metastatic basal cell carcinoma: a systematic review and pooled analysis of interventional studies JAMA Dermatol 2016 152 816 10.1001/jamadermatol.2016.0780 27096888
Jacobsen AA, Aldahan AS, Hughes OB, Shah VV, Strasswimmer J. Hedgehog pathway inhibitor therapy for locally advanced and metastatic basal cell carcinoma: a systematic review and pooled analysis of interventional studies. JAMA Dermatol. 2016;152:816. 10.1001/jamadermatol.2016.0780.27096888
54. Bertrand N Guerreschi P Basset-Seguin N Saiag P Dupuy A Dalac-Rat S Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study) EClinicalMedicine 2021 35 100844 10.1016/j.eclinm.2021.100844 33997740
Bertrand N, Guerreschi P, Basset-Seguin N, Saiag P, Dupuy A, Dalac-Rat S, et al. Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study). EClinicalMedicine. 2021;35:100844. 10.1016/j.eclinm.2021.100844.33997740
55. Singalavanija T Ceylanoglu KS Juntipwong S Beser BG Elner VM Worden FP Review of targeted therapy, vismodegib, for the treatment of periocular basal cell carcinoma Ophthal Plast Reconstr Surg 2023 10.1097/IOP.0000000000002464 37552493
Singalavanija T, Ceylanoglu KS, Juntipwong S, Beser BG, Elner VM, Worden FP, et al. Review of targeted therapy, vismodegib, for the treatment of periocular basal cell carcinoma. Ophthal Plast Reconstr Surg. 2023. 10.1097/IOP.0000000000002464.37552493
56. Sagiv O Ding S Ferrarotto R Glisson B Altan M Johnson F Impact of food and drug administration approval of vismodegib on prevalence of orbital exenteration as a necessary surgical treatment for locally advanced periocular basal cell carcinoma Ophthal Plast Reconstr Surg 2019 35 350 353 10.1097/IOP.0000000000001251 30365473
Sagiv O, Ding S, Ferrarotto R, Glisson B, Altan M, Johnson F, et al. Impact of food and drug administration approval of vismodegib on prevalence of orbital exenteration as a necessary surgical treatment for locally advanced periocular basal cell carcinoma. Ophthal Plast Reconstr Surg. 2019;35:350–3. 10.1097/IOP.0000000000001251.30365473
57. Dika E Scarfì F Ferracin M Broseghini E Marcelli E Bortolani B Basal cell carcinoma: a comprehensive review Int J Mol Sci 2020 21 5572 10.3390/ijms21155572 32759706
Dika E, Scarfì F, Ferracin M, Broseghini E, Marcelli E, Bortolani B, et al. Basal cell carcinoma: a comprehensive review. Int J Mol Sci. 2020;21:5572. 10.3390/ijms21155572.32759706
58. Odom D Mladsi D Purser M Kaye JA Palaka E Charter A A matching-adjusted indirect comparison of sonidegib and vismodegib in advanced basal cell carcinoma J Skin Cancer 2017 2017 1 7 10.1155/2017/6121760
Odom D, Mladsi D, Purser M, Kaye JA, Palaka E, Charter A, et al. A matching-adjusted indirect comparison of sonidegib and vismodegib in advanced basal cell carcinoma. J Skin Cancer. 2017;2017:1–7. 10.1155/2017/6121760.
59. Bossi P Ascierto PA Basset-Seguin N Dreno B Dummer R Hauschild A Long-term strategies for management of advanced basal cell carcinoma with hedgehog inhibitors Crit Rev Oncol Hematol 2023 189 104066 10.1016/j.critrevonc.2023.104066 37442495
Bossi P, Ascierto PA, Basset-Seguin N, Dreno B, Dummer R, Hauschild A, et al. Long-term strategies for management of advanced basal cell carcinoma with hedgehog inhibitors. Crit Rev Oncol Hematol. 2023;189:104066. 10.1016/j.critrevonc.2023.104066.37442495
60. Lacouture ME Dréno B Ascierto PA Dummer R Basset-Seguin N Fife K Characterization and management of hedgehog pathway inhibitor-related adverse events in patients with advanced basal cell carcinoma Oncologist 2016 21 1218 1229 10.1634/theoncologist.2016-0186 27511905
Lacouture ME, Dréno B, Ascierto PA, Dummer R, Basset-Seguin N, Fife K, et al. Characterization and management of hedgehog pathway inhibitor-related adverse events in patients with advanced basal cell carcinoma. Oncologist. 2016;21:1218–29. 10.1634/theoncologist.2016-0186.27511905
61. Lear JT Dummer R Guminski A Using drug scheduling to manage adverse events associated with hedgehog pathway inhibitors for basal cell carcinoma Oncotarget 2021 12 2531 40 10.18632/oncotarget.28145 34966484
Lear JT, Dummer R, Guminski A. Using drug scheduling to manage adverse events associated with hedgehog pathway inhibitors for basal cell carcinoma. Oncotarget. 2021;12:2531–40. 10.18632/oncotarget.28145.34966484
62. Dréno B Kunstfeld R Hauschild A Fosko S Zloty D Labeille B Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial Lancet Oncol 2017 18 404 412 10.1016/S1470-2045(17)30072-4 28188086
Dréno B, Kunstfeld R, Hauschild A, Fosko S, Zloty D, Labeille B, et al. Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial. Lancet Oncol. 2017;18:404–12. 10.1016/S1470-2045(17)30072-4.28188086
63. Bendell J Andre V Ho A Kudchadkar R Migden M Infante J Phase I study of LY2940680, a Smo antagonist, in patients with advanced cancer including treatment-naïve and previously treated basal cell carcinoma Clin Cancer Res 2018 24 2082 2091 10.1158/1078-0432.CCR-17-0723 29483143
Bendell J, Andre V, Ho A, Kudchadkar R, Migden M, Infante J, et al. Phase I study of LY2940680, a Smo antagonist, in patients with advanced cancer including treatment-naïve and previously treated basal cell carcinoma. Clin Cancer Res. 2018;24:2082–91. 10.1158/1078-0432.CCR-17-0723.29483143
64. PellePharm, Inc. Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas (BCC). Identifier: NCT02828111. U.S. National Library of Medicine. 2016.
65. Kim J Tang JY Gong R Kim J Lee JJ Clemons KV Itraconazole, a commonly used antifungal that inhibits hedgehog pathway activity and cancer growth Cancer Cell 2010 17 388 399 10.1016/j.ccr.2010.02.027 20385363
Kim J, Tang JY, Gong R, Kim J, Lee JJ, Clemons KV, et al. Itraconazole, a commonly used antifungal that inhibits hedgehog pathway activity and cancer growth. Cancer Cell. 2010;17:388–99. 10.1016/j.ccr.2010.02.027.20385363
66. Sharpe HJ Pau G Dijkgraaf GJ Basset-Seguin N Modrusan Z Januario T Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma Cancer Cell 2015 27 327 341 10.1016/j.ccell.2015.02.001 25759019
Sharpe HJ, Pau G, Dijkgraaf GJ, Basset-Seguin N, Modrusan Z, Januario T, et al. Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. Cancer Cell. 2015;27:327–41. 10.1016/j.ccell.2015.02.001.25759019
67. Pricl S Cortelazzi B Dal Col V Marson D Laurini E Fermeglia M Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma Mol Oncol 2015 9 389 397 10.1016/j.molonc.2014.09.003 25306392
Pricl S, Cortelazzi B, Dal Col V, Marson D, Laurini E, Fermeglia M, et al. Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma. Mol Oncol. 2015;9:389–97. 10.1016/j.molonc.2014.09.003.25306392
68. Stratigos AJ Sekulic A Peris K Bechter O Prey S Kaatz M Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial Lancet Oncol 2021 22 848 857 10.1016/S1470-2045(21)00126-1 34000246
Stratigos AJ, Sekulic A, Peris K, Bechter O, Prey S, Kaatz M, et al. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol. 2021;22:848–57. 10.1016/S1470-2045(21)00126-1.34000246
69. Stratigos AJ, Sekulic A, Peris K, Bechter O, Prey S, Lewis KD, et al. Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-up. J Am Acad Dermatol. 2023:S0190962223029729. 10.1016/j.jaad.2023.08.111.
70. Chang ALS Tran DC Cannon JGD Li S Jeng M Patel R Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study J Am Acad Dermatol 2019 80 564 566 10.1016/j.jaad.2018.08.017 30145186
Chang ALS, Tran DC, Cannon JGD, Li S, Jeng M, Patel R, et al. Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study. J Am Acad Dermatol. 2019;80:564–6. 10.1016/j.jaad.2018.08.017.30145186
71. Walsh NM Cerroni L Merkel cell carcinoma: A review J Cutan Pathol 2021 48 411 421 10.1111/cup.13910 33128463
Walsh NM, Cerroni L. Merkel cell carcinoma: A review. J Cutan Pathol. 2021;48:411–21. 10.1111/cup.13910.33128463
72. Buder K Lapa C Kreissl MC Schirbel A Herrmann K Schnack A Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging BMC Cancer 2014 14 268 10.1186/1471-2407-14-268 24742330
Buder K, Lapa C, Kreissl MC, Schirbel A, Herrmann K, Schnack A, et al. Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging. BMC Cancer. 2014;14:268. 10.1186/1471-2407-14-268.24742330
73. Kervarrec T Samimi M Guyétant S Sarma B Chéret J Blanchard E Histogenesis of Merkel cell carcinoma: a comprehensive review Front Oncol 2019 9 451 10.3389/fonc.2019.00451 31245285
Kervarrec T, Samimi M, Guyétant S, Sarma B, Chéret J, Blanchard E, et al. Histogenesis of Merkel cell carcinoma: a comprehensive review. Front Oncol. 2019;9:451. 10.3389/fonc.2019.00451.31245285
74. Feng H Shuda M Chang Y Moore PS Clonal integration of a polyomavirus in human Merkel cell carcinoma Science 2008 319 1096 1100 10.1126/science.1152586 18202256
Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. 2008;319:1096–100. 10.1126/science.1152586.18202256
75. Paik JY Hall G Clarkson A Lee L Toon C Colebatch A Immunohistochemistry for Merkel cell polyomavirus is highly specific but not sensitive for the diagnosis of Merkel cell carcinoma in the Australian population Hum Pathol 2011 42 1385 1390 10.1016/j.humpath.2010.12.013 21453956
Paik JY, Hall G, Clarkson A, Lee L, Toon C, Colebatch A, et al. Immunohistochemistry for Merkel cell polyomavirus is highly specific but not sensitive for the diagnosis of Merkel cell carcinoma in the Australian population. Hum Pathol. 2011;42:1385–90. 10.1016/j.humpath.2010.12.013.21453956
76. Iyer JG Blom A Doumani R Lewis C Tarabadkar ES Anderson A Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma Cancer Med 2016 5 2294 2301 10.1002/cam4.815 27431483
Iyer JG, Blom A, Doumani R, Lewis C, Tarabadkar ES, Anderson A, et al. Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma. Cancer Med. 2016;5:2294–301. 10.1002/cam4.815.27431483
77. Rabinowits G Is this the end of cytotoxic chemotherapy in Merkel cell carcinoma? OncoTargets Ther 2017 10 4803 4807 10.2147/OTT.S126640
Rabinowits G. Is this the end of cytotoxic chemotherapy in Merkel cell carcinoma? OncoTargets Ther. 2017;10:4803–7. 10.2147/OTT.S126640.
78. Bhatia S Storer BE Iyer JG Moshiri A Parvathaneni U Byrd D Adjuvant radiation therapy and chemotherapy in Merkel cell carcinoma: survival analyses of 6908 cases from the National Cancer Data Base J Natl Cancer Inst 2016 108 djw042 10.1093/jnci/djw042 27245173
Bhatia S, Storer BE, Iyer JG, Moshiri A, Parvathaneni U, Byrd D, et al. Adjuvant radiation therapy and chemotherapy in Merkel cell carcinoma: survival analyses of 6908 cases from the National Cancer Data Base. J Natl Cancer Inst. 2016;108:djw042. 10.1093/jnci/djw042.27245173
79. Allen PJ Bowne WB Jaques DP Brennan MF Busam K Coit DG Merkel cell carcinoma: prognosis and treatment of patients from a single institution J Clin Oncol 2005 23 2300 2309 10.1200/JCO.2005.02.329 15800320
Allen PJ, Bowne WB, Jaques DP, Brennan MF, Busam K, Coit DG. Merkel cell carcinoma: prognosis and treatment of patients from a single institution. J Clin Oncol. 2005;23:2300–9. 10.1200/JCO.2005.02.329.15800320
80. Lipson EJ Vincent JG Loyo M Kagohara LT Luber BS Wang H PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus, and overall survival Cancer Immunol Res 2013 1 54 63 10.1158/2326-6066.CIR-13-0034 24416729
Lipson EJ, Vincent JG, Loyo M, Kagohara LT, Luber BS, Wang H, et al. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus, and overall survival. Cancer Immunol Res. 2013;1:54–63. 10.1158/2326-6066.CIR-13-0034.24416729
81. Baker M Cordes L Brownell I Avelumab: a new standard for treating metastatic Merkel cell carcinoma Expert Rev Anticancer Ther 2018 18 319 326 10.1080/14737140.2018.1445528 29482384
Baker M, Cordes L, Brownell I. Avelumab: a new standard for treating metastatic Merkel cell carcinoma. Expert Rev Anticancer Ther. 2018;18:319–26. 10.1080/14737140.2018.1445528.29482384
82. D’Angelo SP Bhatia S Brohl AS Hamid O Mehnert JM Terheyden P Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial J Immunother Cancer 2020 8 e000674 10.1136/jitc-2020-000674 32414862
D’Angelo SP, Bhatia S, Brohl AS, Hamid O, Mehnert JM, Terheyden P, et al. Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial. J Immunother Cancer. 2020;8:e000674. 10.1136/jitc-2020-000674.32414862
83. Kaufman HL Russell J Hamid O Bhatia S Terheyden P D’Angelo SP Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial Lancet Oncol 2016 17 1374 1385 10.1016/S1470-2045(16)30364-3 27592805
Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D’Angelo SP, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17:1374–85. 10.1016/S1470-2045(16)30364-3.27592805
84. D’Angelo SP Russell J Hassel JC Lebbe C Chmielowski B Rabinowits G First-line (1L) avelumab treatment in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Preliminary data from an ongoing study J Clin Oncol 2017 35 9530 9530 10.1200/JCO.2017.35.15_suppl.9530
D’Angelo SP, Russell J, Hassel JC, Lebbe C, Chmielowski B, Rabinowits G, et al. First-line (1L) avelumab treatment in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Preliminary data from an ongoing study. J Clin Oncol. 2017;35:9530–9530. 10.1200/JCO.2017.35.15_suppl.9530.
85. Nghiem PT Bhatia S Lipson EJ Kudchadkar RR Miller NJ Annamalai L PD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma N Engl J Med 2016 374 2542 2552 10.1056/NEJMoa1603702 27093365
Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, et al. PD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med. 2016;374:2542–52. 10.1056/NEJMoa1603702.27093365
86. Nghiem P Bhatia S Lipson EJ Sharfman WH Kudchadkar RR Brohl AS Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma J Immunother Cancer 2021 9 e002478 10.1136/jitc-2021-002478 33879601
Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS, et al. Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma. J Immunother Cancer. 2021;9:e002478. 10.1136/jitc-2021-002478.33879601
87. Grignani G Rutkowski P Lebbe C Prinzi N Grob J Tanda ET 545 A phase 2 study of retifanlimab in patients with advanced or metastatic merkel cell carcinoma (MCC) (POD1UM-201) J Immunother Cancer 2021 9 A574 A575 10.1136/jitc-2021-SITC2021.545
Grignani G, Rutkowski P, Lebbe C, Prinzi N, Grob J, Tanda ET, et al. 545 A phase 2 study of retifanlimab in patients with advanced or metastatic merkel cell carcinoma (MCC) (POD1UM-201). J Immunother Cancer. 2021;9:A574–5. 10.1136/jitc-2021-SITC2021.545.
88. Topalian SL Bhatia S Amin A Kudchadkar RR Sharfman WH Lebbé C Neoadjuvant nivolumab for patients with resectable Merkel cell carcinoma in the CheckMate 358 trial J Clin Oncol 2020 38 2476 2487 10.1200/JCO.20.00201 32324435
Topalian SL, Bhatia S, Amin A, Kudchadkar RR, Sharfman WH, Lebbé C, et al. Neoadjuvant nivolumab for patients with resectable Merkel cell carcinoma in the CheckMate 358 trial. J Clin Oncol. 2020;38:2476–87. 10.1200/JCO.20.00201.32324435
89. Saiag P Blom A Combined nivolumab and ipilimumab in non-resectable Merkel cell carcinoma The Lancet 2022 400 976 977 10.1016/S0140-6736(22)01749-4
Saiag P, Blom A. Combined nivolumab and ipilimumab in non-resectable Merkel cell carcinoma. The Lancet. 2022;400:976–7. 10.1016/S0140-6736(22)01749-4.
90. Shalhout SZ Emerick KS Kaufman HL Silk AW Thakuria M Miller DM A retrospective study of ipilimumab plus nivolumab in anti-PD-L1/PD-1 refractory Merkel cell carcinoma J Immunother 2022 45 299 302 10.1097/CJI.0000000000000432 35877101
Shalhout SZ, Emerick KS, Kaufman HL, Silk AW, Thakuria M, Miller DM. A retrospective study of ipilimumab plus nivolumab in anti-PD-L1/PD-1 refractory Merkel cell carcinoma. J Immunother. 2022;45:299–302. 10.1097/CJI.0000000000000432.35877101
91. LoPiccolo J Schollenberger MD Dakhil S Rosner S Ali O Sharfman WH Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series J Immunother Cancer 2019 7 170 10.1186/s40425-019-0661-6 31287031
LoPiccolo J, Schollenberger MD, Dakhil S, Rosner S, Ali O, Sharfman WH, et al. Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series. J Immunother Cancer. 2019;7:170. 10.1186/s40425-019-0661-6.31287031
92. Glutsch V Kneitz H Gesierich A Goebeler M Haferkamp S Becker JC Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma Cancer Immunol Immunother CII 2021 70 2087 2093 10.1007/s00262-020-02832-0 33439294
Glutsch V, Kneitz H, Gesierich A, Goebeler M, Haferkamp S, Becker JC, et al. Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma. Cancer Immunol Immunother CII. 2021;70:2087–93. 10.1007/s00262-020-02832-0.33439294
93. Khaddour K Rosman IS Dehdashti F Ansstas G Durable remission after rechallenge with ipilimumab and nivolumab in metastatic Merkel cell carcinoma refractory to avelumab: Any role for sequential immunotherapy? J Dermatol 2021 48 e80 e81 10.1111/1346-8138.15621 33161593
Khaddour K, Rosman IS, Dehdashti F, Ansstas G. Durable remission after rechallenge with ipilimumab and nivolumab in metastatic Merkel cell carcinoma refractory to avelumab: Any role for sequential immunotherapy? J Dermatol. 2021;48:e80–1. 10.1111/1346-8138.15621.33161593
94. Becker JC Ugurel S Leiter U Meier F Gutzmer R Haferkamp S Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial The Lancet 2023 402 798 808 10.1016/S0140-6736(23)00769-9
Becker JC, Ugurel S, Leiter U, Meier F, Gutzmer R, Haferkamp S, et al. Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial. The Lancet. 2023;402:798–808. 10.1016/S0140-6736(23)00769-9.
95. Akaike T Qazi J Anderson A Behnia FS Shinohara MM Akaike G High somatostatin receptor expression and efficacy of somatostatin analogues in patients with metastatic Merkel cell carcinoma* Br J Dermatol 2021 184 319 327 10.1111/bjd.19150 32320473
Akaike T, Qazi J, Anderson A, Behnia FS, Shinohara MM, Akaike G, et al. High somatostatin receptor expression and efficacy of somatostatin analogues in patients with metastatic Merkel cell carcinoma*. Br J Dermatol. 2021;184:319–27. 10.1111/bjd.19150.32320473
96. Anderson A Qazi J Shantha E Takagishi S Iyer JG Blom A Therapeutic targeting of somatostatin receptors in patients with metastatic Merkel cell carcinoma: A retrospective case series J Clin Oncol 2015 33 e20031 e20031 10.1200/jco.2015.33.15_suppl.e20031
Anderson A, Qazi J, Shantha E, Takagishi S, Iyer JG, Blom A, et al. Therapeutic targeting of somatostatin receptors in patients with metastatic Merkel cell carcinoma: A retrospective case series. J Clin Oncol. 2015;33:e20031–e20031. 10.1200/jco.2015.33.15_suppl.e20031.
97. Weill Medical College of Cornell University. Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer (iPRRT). U.S. National Library of Medicine. 2023.
98. Salavati A Prasad V Schneider C-P Herbst R Baum RP Peptide receptor radionuclide therapy of Merkel cell carcinoma using (177)lutetium-labeled somatostatin analogs in combination with radiosensitizing chemotherapy: a potential novel treatment based on molecular pathology Ann Nucl Med 2012 26 365 369 10.1007/s12149-012-0578-3 22361935
Salavati A, Prasad V, Schneider C-P, Herbst R, Baum RP. Peptide receptor radionuclide therapy of Merkel cell carcinoma using (177)lutetium-labeled somatostatin analogs in combination with radiosensitizing chemotherapy: a potential novel treatment based on molecular pathology. Ann Nucl Med. 2012;26:365–9. 10.1007/s12149-012-0578-3.22361935
99. Johnson DB Puzanov I Kelley MC Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma Immunotherapy 2015 7 611 619 10.2217/imt.15.35 26098919
Johnson DB, Puzanov I, Kelley MC. Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma. Immunotherapy. 2015;7:611–9. 10.2217/imt.15.35.26098919
100. Blackmon JT Dhawan R Viator TM Terry NL Conry RM Talimogene laherparepvec for regionally advanced Merkel cell carcinoma: A report of 2 cases JAAD Case Rep 2017 3 185 189 10.1016/j.jdcr.2017.02.003 28443305
Blackmon JT, Dhawan R, Viator TM, Terry NL, Conry RM. Talimogene laherparepvec for regionally advanced Merkel cell carcinoma: A report of 2 cases. JAAD Case Rep. 2017;3:185–9. 10.1016/j.jdcr.2017.02.003.28443305
101. University of Zurich. T-VEC in Non-melanoma Skin Cancer (20139157 T-VEC). U.S. National Library of Medicine. 2018.
102. Gruppo Oncologico del Nord-Ovest. Window-of-opportunity Study of Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery: the MERCURY Trial. clinicaltrials.gov; 2023.
103. Melanoma and Skin Cancer Trials Limited. A Randomised, Placebo-controlled, Phase II Trial of Adjuvant Avelumab in Patients With Stage I-III Merkel Cell Carcinoma. clinicaltrials.gov. 2023.
104. University of Washington. A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial of Adjuvant Avelumab (Anti-PDL-1 Antibody) in Merkel Cell Carcinoma Patients With Lymph Node Metastases. clinicaltrials.gov. 2023.
105. Merck Sharp & Dohme LLC. A Phase 3 Open-label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) as First Line Therapy in Participants With Advanced Merkel Cell Carcinoma (KEYNOTE-913). clinicaltrials.gov. 2023.
106. 4SC AG. A Phase II, Open Label Study to Investigate the Efficacy and Safety of Domatinostat in Combination With Avelumab in Patients With Advanced Unresectable/Metastatic Merkel Cell Carcinoma Progressing on Anti-PD-(L)1 Antibody Therapy. clinicaltrials.gov. 2023.
107. Kartos Therapeutics, Inc. A Phase 1b/2, Open-Label Study Evaluating the Safety and Efficacy of KRT-232 in Patients With p53 Wild-Type (p53WT) Merkel Cell Carcinoma (MCC) Who Have Failed Anti-PD-1 or Anti-PD-L1 Immunotherapy, or in Combination With Avelumab in MCC Patients Who Are Anti-PD-1 or Anti-PD-L1 Treatment Naïve. clinicaltrials.gov. 2023.
108. O’Connell KA Schmults CD Treatment of metastatic cutaneous squamous cell carcinoma in a solid organ transplant recipient with programmed death-1 checkpoint inhibitor therapy J Eur Acad Dermatol Venereol 2022 36 45 48 10.1111/jdv.17407 34855241
O’Connell KA, Schmults CD. Treatment of metastatic cutaneous squamous cell carcinoma in a solid organ transplant recipient with programmed death-1 checkpoint inhibitor therapy. J Eur Acad Dermatol Venereol. 2022;36:45–8. 10.1111/jdv.17407.34855241
109. O’Connell KA Groover MK Lim S Kus KJB Gupta N Murad F Cost of skin cancer-related dermatological care is higher in transplant recipients compared with nonimmunosuppressed patients J Am Acad Dermatol 2024 90 150 152 10.1016/j.jaad.2023.08.077 37666426
O’Connell KA, Groover MK, Lim S, Kus KJB, Gupta N, Murad F, et al. Cost of skin cancer-related dermatological care is higher in transplant recipients compared with nonimmunosuppressed patients. J Am Acad Dermatol. 2024;90:150–2. 10.1016/j.jaad.2023.08.077.37666426
110. Hanna GJ Dharanesswaran H Giobbie-Hurder A Harran JJ Liao Z Pai L Cemiplimab for kidney transplant recipients with advanced cutaneous squamous cell carcinoma J Clin Oncol 2024 42 1021 1030 10.1200/JCO.23.01498 38252908
Hanna GJ, Dharanesswaran H, Giobbie-Hurder A, Harran JJ, Liao Z, Pai L, et al. Cemiplimab for kidney transplant recipients with advanced cutaneous squamous cell carcinoma. J Clin Oncol. 2024;42:1021–30. 10.1200/JCO.23.01498.38252908
111. Hanna GJ Dharaneeswaran HJ Giobbie-Hurder A Harran JJ Liao Z Pai L Cemiplimab for kidney organ transplant recipients with advanced cutaneous squamous cell carcinoma: CONTRAC-1 J Clin Oncol 2023 41 9519 9519 10.1200/JCO.2023.41.16_suppl.9519
Hanna GJ, Dharaneeswaran HJ, Giobbie-Hurder A, Harran JJ, Liao Z, Pai L, et al. Cemiplimab for kidney organ transplant recipients with advanced cutaneous squamous cell carcinoma: CONTRAC-1. J Clin Oncol. 2023;41:9519–9519. 10.1200/JCO.2023.41.16_suppl.9519.
112. Schenk KM Deutsch JS Chandra S Davar D Eroglu Z Khushalani NI Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for kidney transplant recipients with advanced cutaneous cancers J Clin Oncol 2024 42 1011 1020 10.1200/JCO.23.01497 38252910
Schenk KM, Deutsch JS, Chandra S, Davar D, Eroglu Z, Khushalani NI, et al. Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for kidney transplant recipients with advanced cutaneous cancers. J Clin Oncol. 2024;42:1011–20. 10.1200/JCO.23.01497.38252910
